✦ LIBER ✦

886 THE EFFICACY AND TOLERABILITY OF MIRABEGRON IN PATIENTS WITH OVERACTIVE BLADDER – RESULTS FROM A EUROPEAN–AUSTRALIAN PHASE III TRIAL

✍ Scribed by V. Khullar; J. Cambronero; P. Ströberg; J. Angulo; P. Boerrigter; M.B. Blauwet; M. Wooning

Book ID: 119623221
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 226 KB
Volume: 10
Category: Article
ISSN: 1569-9056
DOI: 10.1016/s1569-9056(11)60870-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and Tolerability of Mirabegron,

Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial

✍ Vik Khullar; Gerard Amarenco; Javier C. Angulo; Javier Cambronero; Kjetil Høye; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 827 KB

Efficacy and Tolerability of Mirabegron,

Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial

✍ Rovner, E.S. 📂 Article 📅 2013 🏛 Elsevier Science ⚖ 51 KB

Re: Efficacy and Tolerability of Mirabeg

Re: Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European-Australian Phase 3 Trial

✍ Wein, Alan J. 📂 Article 📅 2013 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 117 KB

Results of a Randomized Phase III Trial

Results of a Randomized Phase III Trial of Mirabegron in Patients with Overactive Bladder

✍ Nitti, Victor W.; Auerbach, Stephen; Martin, Nancy; Calhoun, Alaina; Lee, Misun; 📂 Article 📅 2013 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 1022 KB

885 THE EFFICACY AND SAFETY OF MIRABEGRO

885 THE EFFICACY AND SAFETY OF MIRABEGRON IN PATIENTS WITH OVERACTIVE BLADDER SYNDROME – RESULTS FROM A NORTH-AMERICAN PHASE III TRIAL

✍ V. Nitti; S. Herschorn; S. Auerbach; M. Ayers; M. Lee; N. Martin 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 195 KB

684 Efficacy of mirabegron in patients w

684 Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder (OAB): Post-hoc analysis of a prospective, randomised European-Australian phase III trial

✍ V. Khullar; J. Cambronero; J. Angulo; M. Wooning; M.B. Blauwet; C. Dorrepaal; N. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 50 KB